{"id":22780,"date":"2025-01-24T18:15:18","date_gmt":"2025-01-24T10:15:18","guid":{"rendered":"https:\/\/flcube.com\/?p=22780"},"modified":"2025-01-24T18:15:19","modified_gmt":"2025-01-24T10:15:19","slug":"novo-nordisk-partners-with-immvention-on-bach1-program-for-sickle-cell-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22780","title":{"rendered":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease"},"content":{"rendered":"\n

Denmark-based Novo Nordisk A\/S (NYSE: NVO<\/a>) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to address significant unmet medical needs in these areas.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the terms of the agreement, Novo Nordisk will obtain an exclusive worldwide license to IMMvention\u2019s BACH1 program, taking over all further development, regulatory submissions, and global commercialization efforts. IMMvention will retain rights to develop certain brain-penetrant BACH1 inhibitors, which have the potential to address central nervous system disorders such as Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative conditions.<\/p>\n\n\n\n

Therapeutic Potential of BACH1 Inhibitors<\/strong>
BACH1 is a key regulator of cellular responses, oxidative stress, and inflammation across multiple disease states, making it an attractive therapeutic target. IMMvention\u2019s orally dosed BACH1 inhibitors, currently in pre-clinical development, have demonstrated the potential to increase fetal hemoglobin levels. This mechanism is believed to ameliorate the pathology of sickle cell disease by reducing the severity of symptoms and improving patient outcomes. The collaboration with Novo Nordisk aims to accelerate the development of these innovative therapies, bringing new treatment options to patients with sickle cell disease and other chronic conditions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement…<\/p>\n","protected":false},"author":1,"featured_media":22782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[87,3272,148,860,24],"class_list":["post-22780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chronic-disease","tag-immvention-therapeutix","tag-novo-nordisk","tag-nyse-nvo","tag-rare-orphan-disease-drugs"],"yoast_head":"\nNovo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease\" \/>\n<meta property=\"og:description\" content=\"Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T10:15:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T10:15:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"612\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease\",\"datePublished\":\"2025-01-24T10:15:18+00:00\",\"dateModified\":\"2025-01-24T10:15:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2401-png.avif\",\"keywords\":[\"Chronic disease\",\"IMMvention Therapeutix\",\"Novo Nordisk\",\"NYSE: NVO\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22780#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22780\",\"name\":\"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2401-png.avif\",\"datePublished\":\"2025-01-24T10:15:18+00:00\",\"dateModified\":\"2025-01-24T10:15:19+00:00\",\"description\":\"Denmark-based Novo Nordisk A\\\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22780\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2401-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2401-png.avif\",\"width\":1080,\"height\":612,\"caption\":\"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease - Insight, China's Pharmaceutical Industry","description":"Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22780","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease","og_description":"Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.","og_url":"https:\/\/flcube.com\/?p=22780","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-24T10:15:18+00:00","article_modified_time":"2025-01-24T10:15:19+00:00","og_image":[{"width":1080,"height":612,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease","datePublished":"2025-01-24T10:15:18+00:00","dateModified":"2025-01-24T10:15:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22780"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","keywords":["Chronic disease","IMMvention Therapeutix","Novo Nordisk","NYSE: NVO","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22780#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22780","url":"https:\/\/flcube.com\/?p=22780","name":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22780#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","datePublished":"2025-01-24T10:15:18+00:00","dateModified":"2025-01-24T10:15:19+00:00","description":"Denmark-based Novo Nordisk A\/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention's expertise in BACH1 inhibition to address significant unmet medical needs in these areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22780"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22780#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","width":1080,"height":612,"caption":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2401-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22780"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22780\/revisions"}],"predecessor-version":[{"id":22783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22780\/revisions\/22783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22782"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}